MarkMendelSklarMD

Endocrinology • Washington, DC

Diabetes, Lipid Metabolism, Thyroid

Mark Sklar, M.D.

Join to view full profile

Dr. Sklar is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Sklar's full profile

Already have an account?

Office
3 Washington Cir NW
Ste 303
Washington, DC 20037
Phone+1 202-887-4769

Fax+1 202-223-2552

Education & Training

National Institutes of Health Clinical CenterFellowship, Endocrinology, Diabetes, and Metabolism, 1987 - 1990
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 1984 - 1987
Mount Sinai Hospital1984 - 1985
Boston UniversityB.A, Summa Cum Laude, 1984 - 1984
Boston University School of MedicineClass of 1984

Certifications & Licensure

NY State Medical License 1985 - Present
VA State Medical License 1990 - 2026
DC State Medical License 1990 - 2024
MD State Medical License 1987 - 2006
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Endocrinology, Diabetes and Metabolism

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
Washingtonian Best Doctors Listing 2002, 2005, 2008, 2010, 2012
American College of Endocrinology-Endocrine Certification in Neck Ultrasound Program 2011
CMS Meaningful Use Stage 1 Certification Practice Fusion EHR, Practice Fusion, Inc., 2011-2012
Phi Beta Kappa
Alpha Omega Alpha Honor Medical Society
Fellowship American College of Physicians
Fellowship American College of Clinical Endocrinology
Most Compassionate Doctor American Registry
Super Doctor SuperDoctors.com
Top MD Consumers Checkbook
Fellow (FACE) American Association of Clinical Endocrinology
Join now to see all

Publications & Presentations

PubMed

Effect of a Dietary Intervention on Insulin Requirements and Glycemic Control in Type 1 Diabetes: A 12-Week Randomized Clinical Trial.
Hana Kahleova, Tatiana Znayenko-Miller, Karen Smith, Cyrus Khambatta, Robby Barbaro
Clinical Diabetes. 2024-01-01
108 citations
Toward improved management of NIDDM: A randomized, controlled, pilot intervention using a lowfat, vegetarian diet.
Andrew S Nicholson, Mark Sklar, Neal D. Barnard, Sarojini Gore, Rick Sullivan
Preventive Medicine. 1999-08-01

Journal Articles

A Doctor’s Reflections on Health-Care Reform.
Sklar, Mark, The Wall Street Journal
The Very-Low Fat, High-Fiber Diet in the Treatment of NIDDM: A Randomized, Controlled, Intervention Study.
Nicholson AS, Sklar MM, Gore S, Sullivan R, Browning S, Journal of Preventive Medicine
Oral Hypoglycemics for NIDDM: Singly, Combined and With Insulin.
Khodor M, and Sklar, MM, Consultant; 35:361-372
Developmental Expression of the Insulin-Like Growth Factor-II/Mannose 6-Phosphate Receptor.
Nissley P, Kiess W, Sklar MM, Molecular Reproduction and Development; 35:408-413
Developmental expression of Rat Insulin-Like Growth Factor-II/Mannose-6-Phosphate Receptor mRNA.
Sklar MM, Thomas CL, Municchi G, Robert CT, LeRoith D, Kiess W, Nissley SP, Endocrinology; 130:3484-3491
Changes in the Expression of Insulin-Like Growth Factor-II/Mannose-6-Phosphate Receptor During Endochondral Bone Development.
Yu YM, Sklar, MM, Nissley SP, Reddi AH, Biochem. Biophys. Res. Commun; 195:516-524
Liver Regeneration Is Associated with Increased Expression of the Insulin-Like Growth Factor-II/Mannose-6-Phosphate Receptor.
Burguera B, Werner H, Sklar MM, Shen O, Stannard B, Roberts CT, Nissley SP, Vore SJ, Caro JF, LeRoith D, Mol. Endocrinol; 4:1539-45
Beta-Galactosidase Decreases the Binding Affinity of the Insulin-Like Growth Factor-II/Mannose-6-Phosphate Receptor for Insulin-Like Growth-Factor II.
Kiess W, Thomas CL, Sklar MM, Nissley, SP, Eur. J. Biochem; 190:71-7
Developmental Expression of the Tissue Insulin-Like Growth Factor-II/Mannose-6-Phosphate Receptor in the Rat: Measurement by Quantitative Immunoblotting.
Sklar MM, Kiess W, Thomas CL, Nissley SP, J. Biol. Chem; 264:16733-8
Insulin-Like Growth Factor-II (IGF-II) Inhibits Both the Cellular Uptake of Beta-Galactosidase and the Binding of Beta-Galactosidase to Purified IGF-II/Mannose-6-Phosp...
Kiess W, Thomas CL, Greenstein LA, Lee L, Sklar MM, Rechler, MM, Sahagian, GG, Nissley, SP, J. Biol. Chem; 264:4710-14
Biochemical Evidence that the Type II Insulin-Like Growth Factor Receptor Is Identical to the Cation-Independent Mannose-6-Phosphate Receptor.
Kiess W, Blickenstaff GD, Sklar MM, Thomas CL, Nissley SP and Sahagian GC, J. Biol. Chem; 263:9339-44
Join now to see all

Books/Book Chapters

Insulin-Like Growth Factors: Molecular and Cellular Aspects.
Chapter: The Insulin-Like Growth Factor-II/Mannose-6-Phosphate Receptor
Page 111 - 150Nissley P, Kiess W, and Sklar MEditors: LeRoith D.CRC Press, Boca Raton

Abstracts/Posters

Increased IGF-II Receptor Gene Expression and Binding During Liver Regeneration.
Burguera B, Werner H, Sklar M, Roberts CT, LeRoith D, The American Diabetes Association Meetings
The Rat Insulin-Like Growth Factor-II (IGF-II)/Mannose-6-Phosphate (M6P) Receptor mRNA Is Developmentally Regulated in Multiple Tissues.
Sklar MM, Thomas CL, Municchi G, Kress W, Nissley SP, Endocrine Society
Evidence that Beta-Galactosidase Inhibits Insulin-Like Growth Factor-II (IGF-II) Binding to the IGF-II/Mannose-6-Phosphate Recognition Site.
Kiess W, Sklar MM, Thomas C, Nissley SP, Endocrine Society
Insulin-Like Growth Factor-II (IGF-II) Inhibits Binding of Beta Galactosidase to the IGF-II/Mannose-6-Phosphate (M6P) Receptor.
Kiess W, Sklar MM, Thomas CL, Lee L, Nissley SP, Endocrine Society
The Rat Insulin-Like Growth Factor II (IGF-II)/Mannose-6-Phosphate (M6P) Receptor Is Developmentally Regulated in Multiple Tissues.
Sklar MM, Kiess W, Thomas CL, Lee L, Nissley SP, Endocrine Society
Join now to see all